Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Ethyol
Amifostine is a cytoprotective agent used to reduce the cumulative renal toxicity associated with repeated administrations of cisplatin in patients with advanced ovarian cancer and to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer. It is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to its active thiol metabolite, WR-1065. WR-1065 is believed to act as a free radical scavenger, protecting normal tissues from damage by chemotherapy and radiation.
Reduces cumulative renal toxicity from cisplatin and xerostomia from head and neck radiation therapy.
Outcome:
May reduce the efficacy of cisplatin
Mechanism:
Unknown
Outcome:
Increased risk of hypotension
Mechanism:
Additive hypotensive effects
Outcome:
May reduce absorption of amifostine
Mechanism:
Altered gastrointestinal pH
Most likely new formulation: None predicted (low confidence)
Based on current usage trends and clinical trial activity, there is a low probability of significant changes to amifostine's regulatory status in the next 5 years.
Cytoprotective Agent, Radioprotector, Chemoprotector
Aminothiol